[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589798":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":44,"responsibleParty":251,"collaborators":30,"id":253,"slug":254,"hasResults":255,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":255,"sex":261,"minAge":262,"maxAge":263,"enrollmentInfo":264,"targetDuration":30,"studyType":267,"phases":268,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":47,"whyStopped":30,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Depemokimab","EXPERIMENTAL","Participants will be administered depemokimab along with standard of care (SoC).",[13],"Drug: Depemokimab",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants will be administered placebo along with SoC.",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Depemokimab as a sterile liquid formulation will be administered.",[9],[26],"GSK3511294",{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo as a sterile 0.9 percent (%) sodium chloride solution will be administered.",[15],null,[32],{"name":33,"affiliation":5,"role":34},"GSK Clinical Trials","STUDY_DIRECTOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":42,"role":38,"phone":43,"phoneExt":30,"email":40},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[45,67,80,94,108,124,137,147,160,173,186,198,210,223,236],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"GSK Investigational Site","RECRUITING","Loxahatchee Groves","Florida","33470","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-80.27977,26.68368,{"lat":57,"lon":56},[60,61,64],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":65,"role":66,"phone":30,"phoneExt":30,"email":30},"Neal Warshoff","PRINCIPAL_INVESTIGATOR",{"facility":46,"status":47,"city":68,"state":49,"zip":69,"country":51,"countryCode":52,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Miami","33155",{"type":54,"coordinates":71},[72,73],-80.19366,25.77427,{"lat":73,"lon":72},[76,77,78],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":79,"role":66,"phone":30,"phoneExt":30,"email":30},"Guillermo Somodevilla",{"facility":46,"status":47,"city":81,"state":82,"zip":83,"country":51,"countryCode":52,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Rock Hill","South Carolina","29732",{"type":54,"coordinates":85},[86,87],-81.02508,34.92487,{"lat":87,"lon":86},[90,91,92],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":93,"role":66,"phone":30,"phoneExt":30,"email":30},"Michael Denenberg",{"facility":46,"status":47,"city":95,"state":96,"zip":97,"country":51,"countryCode":52,"cosmosGeoPoint":98,"geoPoint":102,"contacts":103},"Corsicana","Texas","75110",{"type":54,"coordinates":99},[100,101],-96.46887,32.09543,{"lat":101,"lon":100},[104,105,106],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":107,"role":66,"phone":30,"phoneExt":30,"email":30},"John D Updegrove",{"facility":46,"status":47,"city":109,"state":110,"zip":111,"country":112,"countryCode":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Changsha","Hunan","410015","China","CN",{"type":54,"coordinates":115},[116,117],112.97087,28.19874,{"lat":117,"lon":116},[120,121,122],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":123,"role":66,"phone":30,"phoneExt":30,"email":30},"Yingqun Zhu",{"facility":46,"status":47,"city":125,"state":126,"zip":30,"country":112,"countryCode":113,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Chengdu","Sichuan",{"type":54,"coordinates":128},[129,130],104.06667,30.66667,{"lat":130,"lon":129},[133,134,135],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":136,"role":66,"phone":30,"phoneExt":30,"email":30},"Xiao Liu",{"facility":46,"status":47,"city":125,"state":30,"zip":138,"country":112,"countryCode":113,"cosmosGeoPoint":139,"geoPoint":141,"contacts":142},"610041",{"type":54,"coordinates":140},[129,130],{"lat":130,"lon":129},[143,144,145],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":146,"role":66,"phone":30,"phoneExt":30,"email":30},"fuqiang Wen",{"facility":46,"status":47,"city":148,"state":30,"zip":149,"country":112,"countryCode":113,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Guangzhou","510150",{"type":54,"coordinates":151},[152,153],113.25,23.11667,{"lat":153,"lon":152},[156,157,158],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":159,"role":66,"phone":30,"phoneExt":30,"email":30},"Liping Wei",{"facility":46,"status":47,"city":161,"state":30,"zip":162,"country":112,"countryCode":113,"cosmosGeoPoint":163,"geoPoint":167,"contacts":168},"Hangzhou","310000",{"type":54,"coordinates":164},[165,166],120.16142,30.29365,{"lat":166,"lon":165},[169,170,171],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":172,"role":66,"phone":30,"phoneExt":30,"email":30},"Limin Wang",{"facility":46,"status":47,"city":174,"state":30,"zip":175,"country":112,"countryCode":113,"cosmosGeoPoint":176,"geoPoint":180,"contacts":181},"Jiangmen","529000",{"type":54,"coordinates":177},[178,179],113.08333,22.58333,{"lat":179,"lon":178},[182,183,184],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":185,"role":66,"phone":30,"phoneExt":30,"email":30},"Mingjiang Lin",{"facility":46,"status":47,"city":187,"state":30,"zip":30,"country":112,"countryCode":113,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Jiangxi",{"type":54,"coordinates":189},[190,191],105.19994,33.99934,{"lat":191,"lon":190},[194,195,196],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":197,"role":66,"phone":30,"phoneExt":30,"email":30},"Limin Dong",{"facility":46,"status":47,"city":199,"state":30,"zip":30,"country":112,"countryCode":113,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Mianyang",{"type":54,"coordinates":201},[202,203],104.68168,31.46784,{"lat":203,"lon":202},[206,207,208],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":209,"role":66,"phone":30,"phoneExt":30,"email":30},"Weiguo Xu",{"facility":46,"status":47,"city":211,"state":30,"zip":212,"country":112,"countryCode":113,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Qingyuan","511500",{"type":54,"coordinates":214},[215,216],113.03333,23.7,{"lat":216,"lon":215},[219,220,221],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":222,"role":66,"phone":30,"phoneExt":30,"email":30},"Dongbo Guangdong Tian",{"facility":46,"status":47,"city":224,"state":30,"zip":225,"country":112,"countryCode":113,"cosmosGeoPoint":226,"geoPoint":230,"contacts":231},"Zigong","643036",{"type":54,"coordinates":227},[228,229],104.77689,29.34162,{"lat":229,"lon":228},[232,233,234],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":235,"role":66,"phone":30,"phoneExt":30,"email":30},"Zhiping Deng",{"facility":46,"status":47,"city":237,"state":30,"zip":238,"country":239,"countryCode":240,"cosmosGeoPoint":241,"geoPoint":245,"contacts":246},"Tokyo","140-8522","Japan","JP",{"type":54,"coordinates":242},[243,244],139.69171,35.6895,{"lat":244,"lon":243},[247,248,249],{"name":37,"role":38,"phone":39,"phoneExt":30,"email":40},{"name":62,"role":38,"phone":63,"phoneExt":30,"email":40},{"name":250,"role":66,"phone":30,"phoneExt":30,"email":30},"Masaharu Shinkai",{"type":252,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100589798","phase-3-depemokimab-as-an-extended-treatment-duration-biologic-in-adults-with-chronic-obstructive-pulmonary-disease-copd-and-type-2-inflammation-endura--1-100589798",false,"NCT06959095","Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)","A Randomized, Double-Blind, Placebo- Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Depemokimab In Adult Participants With COPD With Type 2 Inflammation","ENDURA -1","Inclusion Criteria:\n\n* Participants must be greater than or equal to (\\>=) 40 to less than or equal to (\\\u003C=) 80 years of age, at the time of signing the informed consent.\n* Elevated blood eosinophil count (BEC).\n* Moderate to severe COPD with frequent exacerbations, defined as:\n* A clinically documented history of COPD as defined by the American Thoracic Society\u002FEuropean Respiratory Society for at least 1 year\n* A post-bronchodilator forced expiratory volume in one second (FEV1)\u002Fforced vital capacity (FVC) ratio of less than (\\\u003C) 0.70 and a post- bronchodilator FEV1 \\>30 percent (%) and \\\u003C= 80% predicted normal values\n* A well-documented history of at least 2 moderate or 1 severe exacerbation in the 12 months prior to screening\n* COPD assessment test (CAT) score \\>=10 at Visit 1.\n* Smoking status: Current or former cigarette smokers with a history of cigarette smoking of \\>=10 pack-years.\n* Participants should be on optimized inhaler therapy, defined as inhaled corticosteroid (ICS) plus Long-acting muscarinic receptor antagonist (LAMA) plus Long-acting beta2-adrenergic receptor agonist (LABA) either as multiple inhalers or a single combination inhaler for at least 6 months prior to Screening Visit 1.\n* Body mass index (BMI) \\>=16 kilogram per square meter (kg\u002Fm\\^2).\n* Male or eligible female participants.\n\nExclusion Criteria:\n\nThe following subjects are excluded:\n\n* Participants with a current or prior physician diagnosis of asthma.\n* Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease.\n* Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.\n* Lung resection: Participants with a history of, or plan for lung volume reduction surgery \u002F endobronchial valve procedure.\n* Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1.\n* Continuous oxygen: Participants requiring oxygen supplementation for more than 12 hours per day.\n* Cor pulmonale - resulting in right heart failure, severe pulmonary hypertension\n* Chronic hypercapnia requiring Non-invasive positive pressure ventilation (NIPPV) use (including Bi-Level Positive Airway Pressure \\[BiPAP\\] or Continuous Positive Airway Pressure \\[CPAP\\]).\n* Unstable cardiovascular disease or arrhythmia.\n* Parasitic Infection: Participants with a known, pre-existing parasitic infection within 6 months of Screening (Visit 1).","ALL","40 Years","80 Years",{"count":265,"type":266},981,"ESTIMATED","INTERVENTIONAL",[269],"PHASE3","Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.",[272],"Pulmonary Disease, Chronic Obstructive",[9,26,274,275,276,277,278,279,280,15,281],"Eosinophilic phenotype","Chronic obstructive pulmonary disease","(COPD)","Moderate COPD","Severe COPD","Uncontrolled Moderate to Severe Chronic Obstructive Pulmonary Disease","Exacerbations","Type 2 inflammation","2025-10-06",{"date":284,"type":285},"2025-10-08","ACTUAL",{"date":287,"type":285},"2025-06-20",{"date":289,"type":266},"2029-08-20",{"name":5,"class":6},15]